Repositioning Drugs for Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects

Volumn , Issue , 2016, Pages 567-575

  Grammer, Amrie C ^a   Ryals, Matthew M ^a   Catalina, Michelle D ^a   Lipsky, Peter E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Drug repositioning; Drug repurposing; HSCT; Krill oil; Meditation; Mindfulness; Quinacrine; Stelara; Stem cells; Thunder god vine; TwHF

Indexed keywords

EID: 84966862747     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-801917-7.00066-8     Document Type: Chapter

References (71)

1. Lan Langedijk J., Mantel-Teeuwisse A.K., Slijkerman D.S., Schutjens M.H. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 2015, 20(8):1027-1034.
2. Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3:673-683.
3. Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine Drug repurposing and repositioning: Workshop summary August 08, 2014, National Academies Press (US), Washington (DC).
4. Kim J.H., Scialli A.R. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011, 122:1-6.
5. Putinatti M.S., Lastória J.C., Padovani C.R. Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day. An Bras Dermatol 2014, 89:266-272.
6. Bianchi G., Richardson P.G., Anderson K.C. Promising therapies in multiple myeloma. Blood 2015, 126(3):300-310.
7. Baret I., De Haes P. Thalidomide: still an important second-line treatment in refractory cutaneous lupus erythematosus?. J Dermatol Treat 2015, 26:173-177.
8. Cavalla D. Predictive methods in drug repurposing: gold mine or just a bigger haystack?. Drug Discov Today 2013, 18:523-532.
9. Minie M., Chopra G., Sethi G., Horst J., White G., Roy A., et al. CANDO and the infinite drug discovery frontier. Drug Discov Today 2014, 19:1353-1363.
10. Bisgin H., Liu Z., Kelly R., Fang H., Xu X., Tong W. Investigating drug repositioning opportunities in FDA drug labels through topic modeling. BMC Bioinf 2012, 13(Suppl. 15):S6.
11. Hurle M.R., Yang L., Xie Q., Rajpal D.K., Sanseau P., Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013, 93:335-341.
12. Jahchan N.S., Dudley J.T., Mazur P.K., Flores N., Yang D., Palmerton A., et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013, 3:1364-1377.
13. Avorn J. The $2.6 billion pill-methodologic and policy considerations. N Engl J Med 2015, 372:1877-1879.
14. http://pharmatimes.com/article/14-10-02/All_over_for_tabalumab_as_Lilly_drug_now_fails_for_lupus.aspx.
15. Reddy V., Jayne D., Close D., Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013, 15(Suppl. 1):S2.
16. Furie R., Nicholls K., Cheng T.T., Houssiau F., Burgos-Vargas R., Chen S.L., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014, 66:379-389.
17. Kalunian K.C., Merrill J.T., Maciuca R., McBride J.M., Townsend M.J., Wei X., et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2015, [Epub ahead of Print]. 10.1136/annrhuemdis-2014-206090.
18. http://www.forbes.com/sites/bernardmunos/2015/01/02/the-fda-approvals-of-2014/.
19. http://www.centerwatch.com/drug-information/fda-approved-drugs/.
20. Fagnan D.E., Yang N.N., McKew J.C., Lo A.W. Financing translation: analysis of the NCATS rare-diseases portfolio. Sci Transl Med 2015, 7:276.
21. Xu K., Coté T.R. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform 2011, 12:341-345.
22. http://www.nih.gov/science/amp/autoimmune.htm.
23. Andronis C., Sharma A., Virvilis V., Deftereos S., Persidis A. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011, 12:357-368.
24. Khare R., Good B.M., Leaman R., Su A.I., Lu Z. Crowdsourcing in biomedicine: challenges and opportunities. Brief Bioinform 2015, [Epub ahead of Print]. 10.1093/bib/bbv021.
25. Grammer A.C., Ryals M., Lipsky P.E. A comprehensive approach to identify approved drugs and treatments for repositioning as therapies for systemic lupus erythematosus. Arthritis Res Ther 2014, 16(Suppl. 1):A51.
26. Lipsky P.E., Ryals M., Grammer A.C. A novel strategy to identify and evaluate approved drugs and treatments for repositioning as therapies for systemic lupus erythematosus (SLE) 2014, American College of Rheumatology, A674.
27. Smith-Berdan S., Gille D., Weissman I.L., Christensen J.L. Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood 2007, 110:1370-1378.
28. Sui W., Hou X., Che W., Chen J., Ou M., Xue W., et al. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin Immunol 2013, 148:186-197.
29. Muraro P.A., Nikolov N.P., Butman J.A., Abati A., Gea-Banacloche J., Gress R., et al. Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosus. Haematologica 2006, 91(Suppl. 6):ECR21.
30. Collins E., Gilkeson G. Hematopoetic and mesenchymal stem cell transplantation in the treatment of refractory systemic lupus erythematosus-where are we now?. Clin Immunol 2013, 148:328-334.
31. Wang Q., Qian S., Li J., Che N., Gu L., Wang Q., et al. Combined transplantation of autologous hematopoietic stem cells and allogenic mesenchymal stem cells increases T regulatory cells in systemic lupus erythematosus with refractory lupus nephritis and leukopenia. Lupus 2015, 24(11):1221-1226.
32. Weigert O., von Spee C., Undeutsch R., Kloke L., Humrich J.Y., Riemekasten G. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther 2013, 15:R35.
33. Robinson D.R., Prickett J.D., Makoul G.T., Steinberg A.D., Colvin R.B. Dietary fish oil reduces progression of established renal disease in (NZB x NZW)F1 mice and delays renal disease in BXSB and MRL/1 strains. Arthritis Rheum 1986, 29:539-546.
34. Pestka J.J., Vines L.L., Bates M.A., He K., Langohr I. Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse. PLoS One 2014, 9:e100255.
35. Wright S.A., O'Prey F.M., McHenry M.T., Leahey W.J., Devine A.B., Duffy E.M., et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008, 67:841-848.
36. Duffy E.M., Meenagh G.K., McMillan S.A., Strain J.J., Hannigan B.M., Bell A.L. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 2004, 31:1551-1556.
37. Nakamura N., Kumasaka R., Osawa H., Yamabe H., Shirato K., Fujita T., et al. Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis. In Vivo 2005, 19:879-882.
38. Clark W.F., Parbtani A., Huff M.W., Reid B., Holub B.J., Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int 1989, 36:653-660.
39. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997, 94:4312-4317.
40. Hirasawa A. Free fatty acid receptor family: a new therapeutic target for metabolic diseases. Yakugaku Zasshi 2015, 135:769-777.
41. Xue B., Yang Z., Wang X., Shi H. Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLoS One 2012, 7:e45990.
42. Zhang M., Wang S., Mao L., Leak R.K., Shi Y., Zhang W., et al. Omega-3 fatty acids protect the brain against ischemic injury by activating Nrf2 and upregulating heme oxygenase 1. J Neurosci 2014, 34:1903-1915.
43. Bello K.J., Fang H., Fazeli P., Bolad W., Corretti M., Magder L.S., et al. Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int 2013, 33:2789-2796.
44. Brinker A.M., Ma J., Lipsky P.E., Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 2007, 68:732-766.
45. Ma J., Dey M., Yang H., Poulev A., Pouleva R., Dorn R., et al. Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry 2007, 68:1172-1178.
46. Wang Z., Jin H., Xu R., Mei Q., Fan D. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med 2009, 41:717-727.
47. Dai S., Yin K., Yao X., Zhou L. Inhibition of interleukin-13 gene expression by triptolide in activated T lymphocytes. Respirology 2013, 18:1249-1255.
48. Wu C., Xia Y., Wang P., Lu L., Zhang F. Triptolide protects mice from ischemia/reperfusion injury by inhibition of IL-17 production. Int Immunopharmacol 2011, 11:1564-1572.
49. Zhang Y., Ma X. Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. J Immunol 2010, 184:3866-3877.
50. He L., Liang Z., Zhao F., Peng L., Chen Z. Modulation of IL-37 expression by triptolide and triptonide in THP-1 cells. Cell Mol Immunol 2014, 12(4):515-518.
51. Wang B., Ma L., Tao X.L., Lipsky P.E. Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase gene transcription. Arthritis Rheum 2004, 50:2995-3003.
52. Tao X.L., Schulze-Koops H., Ma L., Cai J., Mao Y.P., Lipsky P.E. Effects of Tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 1998, 41:130-138.
53. Qiu D., Zhao G., Aoki Y., Shi L., Uyei A., Nazarian S., et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999, 274:13443-13450.
54. Park B., Sung B., Yadav V.R., Chaturvedi M.M., Aggarwal B.B. Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway. Biochem Pharmacol 2011, 82:1134-1144.
55. Lu Y., Zhang Y., Li L., Feng X., Ding S., Zheng W., et al. TAB1: a target of triptolide in macrophages. Chem Biol 2014, 21:246-256.
56. Tao X., Fan F., Hoffmann V., Gao C.Y., Longo N.S., Zerfas P., et al. Effective therapy for nephritis in (NZB x NZW)F1 mice with triptolide and tripdiolide, the principal active components of the Chinese herbal remedy Tripterygium wilfordii Hook F. Arthritis Rheum 2008, 58:1774-1783.
57. Li Q.Z., Li P., Garcia G.E., Johnson R.J., Feng L. Genomic profiling of neutrophil transcripts in Asian Qigong practitioners: a pilot study in gene regulation by mind-body interaction. J Altern Complement Med 2005, 11:29-39.
58. Dusek J.A., Otu H.H., Wohlhueter A.L., Bhasin M., Zerbini L.F., Joseph M.G., et al. Genomic counter-stress changes induced by the relaxation response. PLoS One 2008, 3:e2576.
59. Bhasin M.K., Dusek J.A., Chang B.H., Joseph M.G., Denninger J.W., Fricchione G.L., et al. Relaxation response induces temporal transcriptome changes in energy metabolism, insulin secretion and inflammatory pathways. PLoS One 2013, 8:e62817.
60. Black D.S., Cole S.W., Irwin M.R., Breen E., St Cyr N.M., Nazarian N., Khalsa D.S., Lavretsky H. Yogic meditation reverses NF-κB and IRF-related transcriptome dynamics in leukocytes of family dementia caregivers in a randomized controlled trial. Psychoneuroendocrinology 2013, 38:348-355.
61. Qu S., Olafsrud S.M., Meza-Zepeda L.A., Saatcioglu F. Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga program. PLoS One 2013, 8:e61910.
62. Kaliman P., Alvarez-López M.J., Cosín-Tomás M., Rosenkranz M.A., Lutz A., Davidson R.J. Rapid changes in histone deacetylases and inflammatory gene expression in expert meditators. Psychoneuroendocrinology 2014, 40:96-107.
63. Greco C.M., Rudy T.E., Manzi S. Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum August 2004, 51:625-634.
64. Bantornwan S., Watanapa W.B., Hussarin P., Chatsiricharoenkul S., Larpparisuth N., Teerapornlertratt T., et al. Role of meditation in reducing sympathetic hyperactivity and improving quality of life in lupus nephritis patients with chronic kidney disease. J Med Assoc Thai 2014, 97(Suppl. 3):S101-S107.
65. Singh V.K., Bhandari R.B., Rana B.B. Effect of yogic package on rheumatoid arthritis. Indian J Physiol Pharmacol 2011, 55:329-335.
66. Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success?. Nat Rev Drug Discov 2009, 8:541-546.
67. Wendler A., Wehling M. Translatability scoring in drug development: eight case studies. J Transl Med 2012, 10:39.
68. Zanin-Zhorov A., Weiss J.M., Nyuydzefe M.S., Chen W., Scher J.U., Mo R., et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA 2014, 111:16814-16819.
69. Stirzaker R.A., Biswas P.S., Gupta S., Song L., Bhagat G., Pernis A.B. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012, 21:656-661.
70. Rabbani M.A., Shah S.M., Ahmad A. Sustained remission in a case of lupus nephritis with cyclosporin therapy. Saudi J Kidney Dis Transpl 2001, 12:525-529.
71. Yap D.Y., Ma M.K., Mok M.M., Kwan L.P., Chan G.C., Chan T.M. Long-term data on tacrolimus treatment in lupus nephritis. Rheumatology 2014, 53:2232-2237.